Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0008991046
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG002NCK5M5
ADMA
ADMA Biologics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ADMA Biologics Inc
ISIN
US0008991046
TICKER
ADMA
MIC
XNAS
REUTERS
ADMA.OQ
BLOOMBERG
ADMA US
Sa., 20.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities c...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 19, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faru...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 18, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

Did you buy ADMA securities between August 9, 2024 and March 25, 2026?Affected ADMA Investor SummaryWho: ADMA Biologics, Inc. (NASDAQ: ADMA)What: Securities fraud class action lawsuit filedClass Period: August 9, 2024 through March 25, 2026Deadline to Seek Lead Plaintiff Status: August 10, 2026Key Lawsuit Allegations: Material misstatements and/or...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities c...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

ADMA Biologics' SEC filings allegedly used boilerplate risk language and selective related party disclosures to obscure a channel stuffing scheme and undisclosed distributor operating from its own headquarters.NEW YORK, June 18, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of ADMA Biologics, Inc.'s (NASDAQ: ADMA) risk disclosures and relat...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       ADMA Biologics
US0008991046

Philadelphia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 18.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       ADMA Biologics
US0008991046

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters.NEW YORK, June 17, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of a pending securities class action. Class Pe...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 17, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Bio...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       ADMA Biologics
US0008991046

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (ADMA Biologics) (NASDAQ: ADMA) on behalf of those who purchased or acquired ADMA Biologics securities between August 9, 2024 and M...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 16, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       ADMA Biologics
US0008991046

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Clas...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 16, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 16.06.2026       ADMA Biologics
US0008991046

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, June 16, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action law...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       ADMA Biologics
US0008991046

Law Offices of Howard G. Smith reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 15, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. This lawsuit seeks to recove...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       ADMA Biologics
US0008991046

Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Atto...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       ADMA Biologics
US0008991046

San Diego, California--(Newsfile Corp. - June 15, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until August 10, 2026 to seek appointment a...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
So., 14.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Sa., 13.06.2026       ADMA Biologics
US0008991046

NEW ORLEANS, June 12, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) ("ADMA" or the "Company"), if they purchased or otherwise acquired the Company'...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Sa., 13.06.2026       ADMA Biologics
US0008991046

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captione...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Sa., 13.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9,2024 and March 25, 2026. ADMA Biologics, Inc., is a biopharmaceutical company, develops, manufactures, and markets spe...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 12, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “C...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a le...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 12, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investor...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).If you suffered a loss on your ADMA investments, you have unti...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       ADMA Biologics
US0008991046

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics who were adverse...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. T...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 11, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics clas...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Boston, Massachusetts--(Newsfile Corp. - June 11, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its executives. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover th...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a lead plaintiff motion.IF YOU...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the trea...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       ADMA Biologics
US0008991046

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ADMA Biologics investors under the federal se...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
So., 07.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink